Copyright © 2026 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{180319,
        author = {Santosh Yadav and Techi Yassa},
        title = {A Systematic Review on Prescription Pattern of Breast Cancer in Indian Hospitals},
        journal = {International Journal of Innovative Research in Technology},
        year = {2025},
        volume = {12},
        number = {1},
        pages = {657-661},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=180319},
        abstract = {Background: In India, breast cancer stands as the most prevalent cancer among women, with an increasing incidence and notable differences in treatment approaches. It is essential to comprehend the trends in chemotherapy and supportive care prescriptions to enhance patient outcomes.            

Objective: This systematic review aims to evaluate the prescribing patterns of chemotherapeutic and supportive drugs in Indian hospitals, examining adherence to treatment protocols and identifying obstacles in breast cancer management.                                                                                         

Material and Methods: A thorough literature review was performed, encompassing peer-reviewed studies published from 2017 to 2024. The review included studies that addressed chemotherapy regimens, hormonal and targeted therapies, adverse drug reactions (ADRs), and compliance with treatment guidelines. Data from the selected studies were analyzed to uncover trends in prescribing practices.   

Results: The most frequently prescribed chemotherapeutic agents were Cyclophosphamide (77-92%) and Doxorubicin (68.57-79.1%), with 5-Fluorouracil (18.75-44.29%) also being commonly utilized. The ACT regimen (Adriamycin, Cyclophosphamide, Taxanes) and the combination of Cyclophosphamide and Doxorubicin were the predominant treatment protocols. Supportive medications, including Dexamethasone (61.2%) and Ondansetron (50.8%), were widely used to alleviate chemotherapy-related toxicities. Despite a strong adherence to established guidelines, challenges such as delays in treatment initiation, non-compliance, and incomplete chemotherapy—especially in rural areas—remain prevalent.    

Conclusion: This study reveals a notable consistency in chemotherapy choices across Indian hospitals, in line with international treatment guidelines. However, variations in prescribing practices are influenced by institutional disparities, resource constraints, and patient-related factors. It is crucial to address issues of non-compliance and treatment discontinuation to enhance breast cancer management and improve patient outcomes in India.},
        keywords = {},
        month = {June},
        }